Linezolid Krka (Linezolid)

Linezolid is used to treat infections caused by Gram‑positive bacteria, particularly those resistant to other agents.

• Complicated skin and soft tissue infections: provides bacterial eradication and clinical cure in affected tissues.
• Community‑acquired and nosocomial pneumonia: improves respiratory outcomes by eliminating the causative pathogens.
• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: achieves effective clearance of resistant staphylococcal strains.
• Vancomycin‑resistant Enterococcus (VRE) infections: offers an alternative therapeutic option when vancomycin is ineffective.
• Other serious Gram‑positive bacterial infections: targets organisms such as Streptococcus pneumoniae and resistant coagulase‑negative staphylococci.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This binding prevents formation of the initiation complex, blocking the translation of essential proteins and halting bacterial growth. The action is bacteriostatic against most susceptible organisms and bactericidal at higher concentrations, providing activity against a broad range of Gram‑positive pathogens, including strains resistant to other antibiotic classes.

Linezolid may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools.
• Headache: transient cranial discomfort.
• Vomiting: occasional emesis.
• Metallic taste: altered taste perception.
• Rash: mild skin eruption.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count.
• Anemia: reduced red blood cell levels.
• Peripheral neuropathy: nerve pain or sensory loss.
• Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents.
• Lactic acidosis: buildup of lactic acid causing metabolic disturbance.
• Severe hypotension: marked drop in blood pressure.

When prescribing Linezolid, clinicians should consider several safety precautions.

• Renal impairment: adjust monitoring and assess renal function regularly.
• Hepatic impairment: evaluate liver enzymes and use with caution in severe disease.
• Hematologic monitoring: perform complete blood counts to detect thrombocytopenia or anemia.
• Concomitant serotonergic drugs: avoid or closely monitor for serotonin syndrome.
• Pregnancy category C: weigh potential benefits against risks before use in pregnant women.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid interacts with several drug classes that may require dose adjustment or avoidance.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of severe hypertensive crisis.
• Serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants, tramadol): can precipitate serotonin syndrome.
• Tyramine‑rich foods: may increase blood pressure when combined with linezolid’s MAO inhibition.

Moderate Interactions (Monitor Closely)

• Warfarin: enhanced anticoagulant effect, monitor INR.
• Rifampin: induces metabolism, may reduce linezolid concentrations.
• NSAIDs: increased risk of bleeding when thrombocytopenia occurs.
• Anticonvulsants (phenytoin, carbamazepine): may lower linezolid levels, monitor efficacy.